1	Rapid nanopore metagenomic sequencing and predictive
2	susceptibility testing of positive blood cultures from intensive care
3	patients with sepsis
4	Authors:
5	Patrick N. A. Harris ^{1,2,3} , Michelle J. Bauer ¹ , Lukas Lüftinger ⁴ , Stephan Beisken ⁴ , Brian M.
6	Forde ¹ , Ross Balch ¹ , Menino Cotta ¹ , Luregn Schlapbach ^{5,6} , Sainath Raman ^{6,7} , Kiran
7	Shekar ^{8,9} , Peter Kruger ^{10,11} , Jeff Lipman ^{1,12,13,14} , Seweryn Bialasiewicz ¹⁵ , Lachlan Coin ¹⁶ ,
8	Jason A. Roberts ^{1,3,13,17} , David L. Paterson ^{1,18} , Adam D. Irwin ^{1,19} .
9	Affiliations:
10	1. University of Queensland, Faculty of Medicine, UQ Centre for Clinical Research, Royal Brisbane and
11	Women's Hospital Campus, Brisbane, Australia
12	2. Central Microbiology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Australia
13	3. Herston Infectious Disease Institute, Royal Brisbane and Women's Hospital Campus, Brisbane, Australia
14	4. Ares Genetics GmbH, Carlbergergasse 66, 1230 Vienna, Austria
15	5. University Children's Hospital Zurich, University of Zurich, Zurich, Switzerland
16	6. Child Health Research Centre, The University of Queensland, Brisbane, QLD, Australia
17	7. Paediatric Intensive Care Unit, Queensland Children's Hospital, South Brisbane, Australia
18	8. Adult Intensive Care Services, The Prince Charles Hospital, Brisbane, Queensland, Australia
19	9. University of Queensland, Faculty of Medicine, Brisbane, Australia
20	10. Intensive Care Unit, Princess Alexandra Hospital, Woolloongabba, QLD, Australia
21	11. Department of Anaesthesiology and Critical Care, The University of Queensland, St Lucia, QLD, Australia
22	12. Intensive Care Unit, Royal Brisbane and Women's Hospital, Brisbane, Australia
23	13. Division of Anaesthesiology Critical Care Emergency and Pain Medicine, Nîmes University
24	Hospital, University of Montpellier, Nîmes France
25	14. Jamieson Trauma Institute, Royal Brisbane and Women's Hospital, Brisbane, Australia
26	15. University of Queensland, Faculty of Science, School of Chemistry and Molecular Biosciences, Australian
27	Centre for Ecogenomics, St Lucia, Brisbane, Australia

- 28 16. Department of Microbiology and Immunology, The Peter Doherty Institute for Infection and Immunity,
- 29 University of Melbourne, Melbourne, VIC, Australia
- 30 17. Departments of Pharmacy and Intensive Care Medicine, Royal Brisbane and Women's Hospital, Brisbane,
- 31 Australia
- 32 18. ADVANCE-ID, Saw Swee School of Public Health, National University of Singapore, Singapore
- 33 19. Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, QLD, Australia
- 34
- 35 Keywords: long-read whole genome sequencing, bloodstream infection, artificial
 36 intelligence, machine-learning, nanopore
- 37

38 ABSTRACT

- 39 Background: Direct metagenomic sequencing from positive blood culture (BC) broths, to
- 40 identify bacteria and predict antimicrobial susceptibility, has been previously demonstrated

41 using Illumina-based methods, but is relatively slow. We aimed to evaluate this approach

42 using nanopore sequencing to provide more rapid results.

43 **Methods**: Patients with suspected sepsis in 4 intensive care units were prospectively enrolled.

44 Human-depleted DNA was extracted from positive BC broths and sequenced using nanopore

45 (MinION). Species abundance was estimated using Kraken2, and a cloud-based artificial

46 intelligence (AI) system (AREScloud) provided *in silico* antimicrobial susceptibility testing

47 (AST) from assembled contigs. These results were compared to conventional identification

48 and phenotypic AST.

49 **Results**: Genus-level agreement between conventional methods and metagenomic whole

50 genome sequencing (MG-WGS) was 96.2% (50/52), but increased to 100% in

51 monomicrobial infections. In total, 262 high quality AREScloud AST predictions across 24

- 52 samples were made, exhibiting categorical agreement (CA) of 89.3%, with major error (MA)
- and very major error (VME) rates of 10.5% and 12.1%, respectively. Over 90% CA was

54	achieved for some taxa (e.g. Staphylococcus aureus), but was suboptimal for Pseudomonas
55	aeruginosa (CA 50%). In 470 AST predictions across 42 samples, with both high quality and
56	exploratory-only predictions, overall CA, ME and VME rates were 87.7%, 8.3% and 28.4%.
57	VME rates were inflated by false susceptibility calls in a small number of species / antibiotic
58	combinations with few representative resistant isolates. Time to reporting from MG-WGS
59	could be achieved within 8-16 hours from blood culture positivity.
60	Conclusions: Direct metagenomic sequencing from positive BC broths is feasible and can
61	provide accurate predictive AST for some species and antibiotics, but is sub-optimal for a
62	subset of common pathogens, with unacceptably high VME rates. Nanopore-based
63	approaches may be faster but improvements in accuracy are required before it can be
64	considered for clinical use. New developments in nanopore sequencing technology, and
65	training of AI algorithms on larger and more diverse datasets may improve performance.
66	Abstract word count: 311

67 **INTRODUCTION**

Sepsis is a major cause of morbidity and mortality. Rapid pathogen identification and antimicrobial susceptibility phenotyping is critical to selection of appropriate treatment and ensuring optimal patient outcomes (1, 2). Current pathogen identification and culture-based antimicrobial susceptibility testing (AST) can take up to 3 days, or longer. Consequently, rapid molecular detection and gene profiling methodologies are needed (2-4), especially in an era of an increasing prevalence of antimicrobial resistance.

74

75 We have previously demonstrated the application of Illumina-based sequencing from positive 76 blood culture broths (5). This approach showed reasonable performance in both species-level 77 identification and predictive AST from metagenomic data, but there were few advantages 78 over conventional methods in terms of turn-around times to clinical reporting. In this study, 79 we aimed to evaluate the use of nanopore sequencing, using a similar approach and an 80 established DNA extraction method, to determine whether reductions in turn-around times 81 can be achieved without sacrificing diagnostic performance. We compared a machine-82 learning based whole genome sequencing predictive AST tool to conventional culture-based 83 methods, in order to determine whether such methods could be applicable in a diagnostic 84 laboratory and achieve acceptable performance characteristics.

85

86 **METHODS**

This was a sub-study of the DIRECT program: a prospective, observational multicentre study of children and adults presenting to the intensive care unit (ICU) with clinical features of sepsis (6). Patients were screened for enrolment in four ICUs (3 adult, 1 paediatric) in Brisbane, Australia (Royal Brisbane and Women's Hospital, The Prince Charles Hospital,

91 Princess Alexandra Hospital and Queensland Children's Hospital). Patients who met
92 inclusion criteria and none of the exclusion criteria were eligible for enrolment (Table 1).

- 93
- 94 Ethics

95 Ethics approval was granted by the Children's Health Queensland Hospital and Health 96 Service Human Research Ethics Committee (HREC) [HREC/19/QCHQ/55177], with 97 governance approvals for all participating sites. Written informed consent was obtained from 98 all participants (or their parent or legal guardian). Approval was granted by the Queensland 99 Civil and Administrative Tribunal [CRL024-19] to include patients unable to consent for 100 themselves under the Guardianship and Administration Act 2000.

101

102 Sampling

This study included patients with positive blood cultures and presence of bacteria confirmed by Gram stain and microscopy. Samples with non-bacterial species (e.g. *Candida*) were excluded from further analysis (as the analysis pipelines are optimised for prokaryotic organisms). Samples with likely contamination (e.g. mixed coagulase-staphylococci), which were not worked-up further by the clinical lab for identification or susceptibility testing, were also not analysed further. For some samples, susceptibility testing was not routinely performed on cultured isolates (e.g. anaerobes), hence predictive AST was not assessed.

110

Blood culture bottles (FA plus, FN plus and paediatric PF plus bottles; bioMérieux) were removed from BACT/Alert Virtuo System once flagged positive with microbial growth on Gram stain. A de-identified 10 mL aliquot of the positive blood culture broth was processed by a blinded researcher in a separate research lab (The University of Queensland, Centre for Clinical Research), located on the same campus, within 1.5 hours (Figure 1). An uninoculated

116 blood culture broth was also sampled to determine the extent of background DNA 117 contamination. Methods for DNA extraction have been detailed previously (5). In brief, host 118 genomic DNA (gDNA) was depleted using the MolYsis Complete and MolYsis Basic kits 119 (Molzym, Germany) 0.2mL and 1mL protocols, respectively, according to manufacturer's 120 instructions, (with minor modifications), then centrifuged at 10,000g for 30 seconds and the 121 supernatant removed (5). The microbial pellet then underwent further gDNA extraction using 122 UltraClean kits. Samples were extracted for genomic DNA upon receipt and the remaining 123 sample frozen at -80°C, and if required, thawed to room temperature from frozen.

124

125 DNA quality and purity checks were undertaken using the QUBIT fluorometer (Life 126 Technologies), NanoDrop 2000 Spectrophotometer (Thermo Scientific) and Agilent 127 TapeStation 4150 using Genomic DNA ScreenTape and Reagents. For comparison, cultured 128 isolates from the positive BC broths were also retrieved from the clinical laboratory for WGS 129 (Figure 1).

130

131 Sequencing

132 Libraries were prepared using the Rapid Barcoding Sequencing or Nanopore Genomic DNA 133 Ligation kit with Native barcoding according to manufacturer's instructions (Oxford 134 Nanopore Technologies). Libraries were loaded into the R9.4.1 flow cell and run on the 135 MinION MK1B device. After flow cell quality checks, all sequencing utilised the flow cell 136 priming kit (EXP-FLP002) and sequencing commenced at -180mV; voltage drift was 137 accounted for where the flow cell went through a wash protocol. The sequencing runs were 138 monitored with MinKNOW version 21.05.25 core 4.3.12. Fast basecalling model was 139 applied with Bream version 6.2.6 and Guppy version 5.0.16 (version 3.2.9 used prior to 140 February 2021). Libraries were run for 72 hours. Final run QC analysis was undertaken with

PycoQC prior to bioinformatic analysis. In addition, pure colonies of bacteria isolated from positive blood cultures were also sequenced, using DNA extracted by QIAGEN DNeasy Ultraclean Microbial Kit, with quantification by Life Technologies QUBIT fluorometer and library preparation with Illumina ILMN DNA LP tagmentation. Library size was determined by Agilent TapeStation 4150 using D1000 High Sensitivity kit. Sequencing was performed on the Illumina MiniSeq platform with the 300 cycle output reagent kit (Figure 1).

147

148 Metagenome assemblies, taxonomic profiling and WGS-AST using machine-learning

149 Assembly and binning for WGS-AST from metagenomes was performed using a previously 150 published workflow (7). Raw reads were trimmed and quality filtered using Nanofilt 2.8 (8), 151 and mapped against the GRCh38 genome using minimap 2.24 (9) to remove host reads. 152 Where possible given input sequencing depth, retained reads were assembled with flye 2.9 153 (10) and parameters "--nano-raw --meta -- iterations 3". Whole metagenome assemblies were 154 polished with Oxford Nanopore Medaka 1.6.1 and parameters "-m r941_min_fast_g303" (11, 155 12). Binning of assembled metagenomes into metagenomic bins was performed with MaxBin 156 2.2.7 (13) and MetaBAT 2.15 (12). Bins were unified using DASTool 1.1.5 (14). Resulting 157 bins were post-processed to improve retainment of AMR marker genes from high quality 158 unbinned contigs, as previously described (7). Taxonomy was assigned using Kraken2 (15) 159 and visualised using Krona plots (https://fordegenomics.github.io/direct). Completeness and 160 duplication of bins was assessed with BUSCO (16) and QUAST (17). For each sample, no 161 more than one resulting bin had genome quality metrics compatible with downstream AST 162 prediction. Downstream analysis was thus performed on whole metagenome assemblies to 163 reduce loss of AMR information in the binning process. Metagenome assemblies were 164 uploaded to the AREScloud web application, release 2022-10 (Ares Genetics GmbH, Vienna, 165 AT) for genomic prediction of antimicrobial susceptibility. The platform used stacked

166 classification machine learning (ML) WGS-AST models trained on ARESdb (18), combined 167 with rule-based resistance prediction via ResFinder 4 (19) to provide species-specific 168 susceptibility/resistance (S/R) predictions. If no high-quality ML models were available in 169 AREScloud for certain taxa, non-specific ResFinder 4 calls based only on generalized 170 presence of antibiotic resistance genes were used, but were flagged as being lower confidence 171 predictions. Where sequence data from cultured isolates and paired BC broth samples were 172 available, in silico resistance gene profiles were determined by screening the draft assembled 173 genomes against the NCBI resistance gene database using AMRFinderPlus (version 3.10.24) 174 (20) with default parameters (90% sequence identity and 90% sequence coverage) and 175 compared for concordance in the presence / absence of AMR genes across the sample types.

176

177 AST predictions for a total of 25 antibiotic compounds were generated, where appropriate 178 and relevant for that species. True negatives (TN) were defined as data points where both the 179 reference method (phenotypic AST) and the test method (AREScloud) returned a negative 180 (i.e. susceptible) result; true positives (TP) where both methods returned a positive (i.e. 181 resistant) result; false positives (FP) where the reference method returned a negative and the 182 tested method returned a positive result; false negatives (FN), where the reference method 183 returned a positive and the tested method returned a negative result. Very major error (VME) 184 and major error (ME) rates were defined following CLSI M52 guidelines (21) as the fraction 185 of cases identified as resistant by the reference method which were identified as susceptible 186 by the tested method (FN / (FN +TP)), and the fraction of cases identified as susceptible by 187 the reference method which were identified as resistant by the tested method (FP / (FP + 188 TN)), respectively. Categorical agreement (CA) between results of WGS-AST and conventional AST were calculated (CA = (TN + TP) / (TN + FP + FN + TP)) for 189 190 antimicrobial-organism combinations.

191

192 Conventional species identification and AST

193 All genomics based species identification and AST results were compared to conventional 194 phenotypic methods validated for clinical use at Pathology Queensland. Species identification 195 was performed using MALDI-TOF (Vitek MS, bioMérieux) on pure cultured isolates, with 196 AST performed by Vitek 2 automated broth microdilution (N-246 AST cards; bioMérieux), 197 using EUCAST clinical breakpoints applicable at the time (22). For certain species (e.g. 198 Streptococcus pyogenes) AST was undertaken using disk diffusion according to EUCAST 199 methods (23), or by Etest (bioMérieux) where appropriate (e.g. penicillin for *Streptococcus* 200 pneumoniae). For some species where EUCAST breakpoints were not available (e.g. 201 Aeromonas spp.), CLSI breakpoints were applied. Conventional phenotypic testing reported 202 for clinical use by the diagnostic laboratory was considered the reference standard against 203 which genomic results were compared.

204

205 **RESULTS**

206 Blood Culture Microorganisms

A total of 66 positive blood culture samples, from 201 enrolled patients, demonstrated bacterial growth, from which 52 were included for further MG-WGS analysis, with exclusions reflecting non-bacterial growth (e.g. *Candida* sp.), missing samples or likely contaminants (e.g. mixed coagulase-negative staphylococci) that were not worked up further by the clinical laboratory (Figure 2; Supplementary Table S1). Samples included 27 grampositive and 23 gram-negative bacterial species, with 2 samples showing polymicrobial growth (Table 2).

215 Taxonomy identification of metagenomic samples and *in silico* predictive AST

216 Samples were run either on a single flow cell, or multiplexed with up to 12 samples per flow 217 cell, with a median sequencing yield per flow cell of 2.5 Gbp for multiplexed samples, and 218 1.5 Gbp for single samples. Taxonomic identification of metagenomic samples yielded 219 excellent agreement to genus level compared to conventional methods (50/52, 96.2%); for 220 monomicrobial samples agreement was 100% (50/50). In two samples, genus-level 221 agreement was obtained, with sequencing provided a more refined identification; the pipeline 222 identified species belonging to Enterobacter cloacae complex (E. hormaechei for sample 223 9420-58 and E. asburiae for sample 9420-32) in two samples reported as E. cloacae by 224 phenotypic methods. The correct species level identity resulting from MG-WGS of both 225 samples was confirmed by sequencing of the cultured isolates. For one polymicrobial sample 226 the secondary pathogen (E. cloacae) reported by phenotypic methods was not apparent in the 227 Kraken2 report of input reads, where only one of the cultured pathogens (E. coli) was 228 identified. For another polymicrobial sample, the presence of Staphylococcus hominis was 229 identified by phenotypic methods alongside *Proteus mirabilis*, but only ~ 15% of bacterial 230 reads in the sample could be matched to genus *Staphylococcus* and were insufficient for 231 predictive MG-AST. For one sample (9421-30), no identification was achieved due to 232 inadequate input data; with only 145 very short reads (mean read length 191), thus no further 233 processing was possible. Sequencing from an uninoculated blood culture broth revealed a 234 very low number of reads (n=28) mapping to bacterial genomes (e.g. *E. coli*), compared to a 235 mean number of reads of 271411 mapping to bacterial taxa for positive culture broths 236 included in the MG-AST analysis.

237

A total of 470 phenotypic AST results with matched metagenomic AST calls were analysed.

As conventional AST was not routinely performed in all samples (e.g. likely contaminants,

240	anaerobic organisms), predictive MG-AST was only compared where phenotypic results
241	were available. In addition, 2 polymicrobial samples were excluded. For an additional 6
242	samples, neither exploratory nor high quality MG-AST predictions, were available (4
243	samples had insufficient reads for assembly and in 2 samples, antibiotics reported by
244	phenotypic methods, were not available in the AREScloud database). As such, a total of 42
245	samples had both MG-AST and phenotypic AST calls compared, and for 24 samples, high
246	quality AREScloud predictions were available.
247	
248	Overall CA was 89.3% for 262 AST results across 24 samples for which quality MG-AST
249	predictions were available, including 7 common BSI organisms (Staphylococcus aureus,
250	Enterococcus faecalis, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae,
251	Streptococcus pneumoniae and Pseudomonas aeruginosa), but with 12.1% VMEs (mainly
252	seen in E. coli with tobramycin and trimethoprim-sulfamethoxazole, driven by a single E. coli
253	sample with poor assembly metrics) and 10.5% MEs (mainly seen in <i>P. aeruginosa</i> against
254	cefepime, ciprofloxacin, gentamicin and meropenem, K. aerogenes against ceftazidime and
255	ceftriaxone, E. coli against amikacin, cephazolin, ampicillin and cefoxitin, and K.
256	pneumoniae against cephazolin and ciprofloxacin) (Tables 3 and 5; Supplementary Table S2).
257	
258	For all 470 AST predictions across 42 samples, including both high-quality and exploratory-
259	only results, CA was 87.7%, with 28.4% VME and 8.3% MEs (Table 4). VMEs were mainly
260	seen with one isolate of Aeromonas sp. (100%; false susceptibility for amoxicillin-
261	clavulanate, meropenem and trimethoprim), Pseudomonas aeruginosa (100%; false
262	susceptibility for ticarcillin-clavulanate), E. coli (31.6%; false susceptibility for tobramycin,
263	trimethoprim-sulfamethoxazole and ticarcillin-clavulanate), Ochrobactrum anthropi (33.3%;
264	false susceptibility for ceftriaxone), Staphylococcus haemolyticus (50%; false susceptibility

265	for cephalothin, ciprofloxacin, rifampicin, tetracycline) and Staphylococcus epidermidis
266	(20%; false susceptibility for cephalothin, ciprofloxacin and teicoplanin). MEs were seen in
267	Pseudomonas aeruginosa (45.5%; false resistance for cefepime, ceftazidime, ciprofloxacin,
268	meropenem) and Klebsiella pneumoniae (11.1%, false resistance for cephazolin, cefoxitin
269	and ciprofloxacin) (Supplementary Table S2). Not all of the tested compounds achieved
270	satisfactory performance even when high quality predictions were achieved, with CA ranging
271	from >95% (for amoxicillin-clavulanate, gentamicin, erythromycin, fusidic acid, ticarcillin-
272	clavulanate and vancomycin) to as low as 55.6% for cephazolin, with high rates of VMEs for
273	trimethoprim-sulfamethoxazole (66.7%), trimethoprim (25%) and tobramycin (100%) (Table
274	6). The only agents that would pass acceptance criteria (>95% CA, <3% ME and <1.5%
275	VME) even when only using high quality predictions, would be amoxicillin-clavulanate,
276	erythromycin and fusidic acid. While vancomycin and ticarcillin-clavulanate had 100% CA
277	and no MEs, the lack of resistant isolates precluded calculation of the rate of VMEs.
278	
279	Detection of AMR genes from nanopore generated assemblies of bacterial genomes from BC
280	broths showed some discrepancies compared to Illumina-based sequencing of pure cultured
281	isolates (Figure 3), although several of these reflected more specific allele calls from
282	sequencing pure isolates (e.g. bla_{CTX-M} from MG-WGS, but $bla_{CTX-M-15}$ from pure isolate).
283	Illumina-based WGS of pure isolates detected a median of 3 additional AMR gene targets
284	(range -1 to 14; IQR 1-5). In only a single sample did nanopore detect one more AMR gene
285	target than Illumina.
286	
287	In terms of potential turn-around times for direct nanopore sequencing from blood cultures;
288	pre-sequencing steps took ~4 hours, including: a) host DNA reduction, ~2 hours, b) DNA

289 Extraction, ~30 minutes, c) DNA amplification, ~1 hour, and d) DNA Library prep, ~30

minutes. Adequate data for downstream processing would usually be achieved within ~4
hours, but flow cells were run up to 12 hours for single samples, and 72 hours for multiplexed
samples. The predictive MG-AST calls from AREScloud were available within ~ 1 hour. As
such, the potential turn-around time from flagging of a positive blood culture to report
generation, could be achieved within 9-17 hours, potentially faster than conventional AST
methods and Illumina-based methods (up to 48 hours, or longer).

296

297 **DISCUSSION**

298 We describe a nanopore-based MG-WGS approach using positive blood culture broth for 299 pathogen detection and taxonomic classification In monomicrobial infections, the 300 performance is encouraging, with 100% agreement to genus level. Polymicrobial samples 301 remain challenging, with only one of two pathogens identified in samples encountered in this 302 study. In two samples with species belonging to the E. cloacae complex, MG-WGS 303 identification was more accurate than conventional methods, although discrimination by 304 MALDI-TOF of these species is known to be problematic, without additional analysis (24, 305 25). Sequencing directly from blood samples to detect pathogenic bacteria in patients with 306 sepsis and bloodstream infection, is limited by low loads of bacterial DNA in blood at the 307 time of presentation, high concentrations of human DNA and challenges in discriminating 308 background low-level contaminating DNA (26, 27). Adding a culture-amplification step by 309 sequencing from positive blood culture broths, as described in this study, increases the 310 amount of bacteria DNA available for sequencing.

311

A key advance in the application of metagenomic diagnostics direct from clinical samples, would be the ability to accurately predict antimicrobial susceptibility, independently of conventional culture-based methods. However, the presence or absence of resistance genes

does not always predict the phenotype, which may be modified by gene expression, gene copy number and other post-translational effects (28). The machine-learning algorithm used in this study is based on a large sample bank with matched whole genome sequenced clinical isolates and AST results collected from several international centres (18). Such an approach has advantages in that the algorithm does not require a clear understanding of the association between genotype and phenotype, but will learn to use relevant genomic features if supplied with adequate amounts of data.

322

323 The use of direct metagenomic sequencing and WGS-AST from positive blood culture broths 324 holds some promise, and nanopore long-read sequencing using MinION offers potential time 325 advantages over Illumina-based approaches. Accuracy of pathogen identification was similar 326 to results previously achieved with Illumina (95% species-level agreement) (5). However, 327 using nanopore sequencing chemistries, flow cells and base-callers available at the time of 328 study, MG-AST predictions based on nanopore data were considerably less accurate than 329 Illumina-based methods, where CA of >95% was demonstrated for common gram-negative 330 pathogens against 17 antimicrobials (with an overall 11% VME rate) (5). Nanopore 331 sequencing in some samples resulted in significant fragmentation and incompleteness of 332 assembled genomes, caused by an insufficient number of reads and low average read length 333 in a subset of data, as well as lower depth of sequencing compared with Illumina. In addition, 334 reads overall exhibited low per-base accuracy (average Phred score of 10.48, i.e. 335 approximately 90% accuracy), likely due to base-calling with the "fast" profile and the use of 336 an older versions of the Guppy base-caller (v5.0.16; and v3.2.9 used in earlier sequencing 337 runs). Additional work is needed to assess the performance of current nanopore consumables 338 (e.g. R10.4.1 flow cells and kit 14 chemistry), which are reported to achieve very high 339 sequencing accuracies (29), and more current base-calling software. The high rates of

340 MEs/VMEs encountered in common species in this study, would currently preclude 341 application for clinical use. CLSI M52 guidelines recommend that new AST systems 342 demonstrate CA \geq 90% and rates of MEs and VMEs <3% (21), although given the high risk 343 of VMEs to patient care, the FDA stipulates VME rates to be <1.5% (30). However, it 344 should be noted that some of these errors occurred in less critical or uncommonly prescribed 345 species/antibiotic combinations (e.g. E. coli and tobramycin). It is hoped that errors could 346 also be mitigated by database enhancement and training of the algorithms on a larger number 347 and broader range of organisms. The application of sequencing from blood cultures may also 348 allow faster identification of slow-growing or fastidious organisms. One potential approach to 349 reduce time to reporting, might be the early sampling of blood culture broths, before they flag 350 positive on automated detections systems. In this way, there may be adequate pathogen load 351 to undertake sequencing, while reducing the overall turn-around time.

352

353 Limitations to this study are acknowledged. While samples included in the study were 354 prospectively collected, and included most common species causing sepsis, a more extensive 355 range of pathogens, including diverse AMR phenotypes would need to be assessed to 356 understand the reliability, broader applicability and clinical utility of this approach. 357 Furthermore, our collection included few samples with resistance to some agents, inflating 358 VME rate in some species/antibiotic combinations. For example, there were only two 359 *Pseudomonas aeruginosa* isolates with resistance to any antimicrobial tested; with resistance 360 to ticarcillin-clavulanate that were both falsely reported as susceptible by MG-AST, leading 361 to a 100% VME rate (albeit only from low-quality exploratory predictions). The absence of 362 any resistances in the *Pseudomonas* samples to other agents precluded the ability to calculate 363 any VMEs for other antibiotics using high-quality predictions. It is also acknowledged that 364 Vitek 2 AST is not a reference method for MIC determination (such as broth microdilution or

agar dilution) and is an imperfect standard for comparison, despite being commonly used in clinical diagnostic laboratories. Additionally, improvements in nanopore flow cell technology have occurred since this study was performed, including the possibility of adaptive sequencing that can actively exclude human DNA during the sequencing process (31), which may also further improve the application of these methods.

370

371 Conclusions

372 Direct metagenomic sequencing from positive blood culture broths in patients with sepsis is

feasible and can provide accurate species-level identification of causative pathogens,

374 especially in monomicrobial infections. Predictive AST shows promise for some bacterial

375 species and antibiotic combinations, but is sub-optimal for a number of common pathogens

376 with unacceptably high VME rates driven by less reliable calls for certain species and drug

377 combinations. Diagnostic performance characteristics were marginally improved by only

378 accepting results where high-quality predictions were available. Nanopore-based approaches

379 may be faster and provide data in real time, but improvements in accuracy across a broader

380 range of organisms are required before it can be considered for clinical use. Improved

381 performance should be achievable with training of ML algorithms on larger and more diverse

datasets, and masking of results where poor performance of certain species and drug

383 combinations are recognised. Furthermore, ongoing developments in the accuracy of rapid

sequencing technologies, should lead to improved performance of these methods for eventualdiagnostic use.

386

387 Acknowledgements and funding

This work was funded by a grant from the Queensland Genomics Health Alliance (QGHA;
subsequently Queensland Genomics) clinical implementation, innovation and incubation

390 program and by a Brisbane Diamantina Health Partners Health System Improvement Ideas 391 Grant (MRFF Rapid Applied Research Translation Program). Patrick Harris was supported 392 by an Early Career Fellowship from the National Health and Medical Research Council 393 (GNT1157530). Jason Roberts would like to acknowledge funding from the Australian 394 National Health and Medical Research Council for a Centre of Research Excellence 395 (APP2007007) and an Investigator Grant (APP2009736) as well as an Advancing 396 Queensland Clinical Fellowship. Adam Irwin is supported by a National Health and Medical 397 Research Council Investigator grant (GNT1197743). We would like to acknowledge the input 398 and support of Thom Cuddihy, Cameron Buckley, Jason Meyer, Kara Brady, Cheryl Fourie, 399 Natalie Sharp, Luminita Vlad, Scott A. Beatson, Julia Clark, Krispin Hajkowicz, Haakon 400 Bergh and David Whiley.

401

402 **Data availability**

- 403 Raw sequence reads have been uploaded to NCBI under Bioproject PRJNA982891.
- 404 Taxonomic classifications for blood culture samples can be visualised here:
- 405 <u>https://fordegenomics.github.io/direct</u>

406

407 **Conflicts of interest**

Lukas Lüftinger and Stephan Beisken are employees of Ares Genetics. Patrick Harris reports research grants from Gilead, and has served on advisory boards for OpGen, Merck and Sandoz, has received honoraria from OpGen, Sandoz, Pfizer and BioMerieux. David Paterson reports grants from Shionogi, Pfizer, Merck and bioMerieux, and consultancies with the AMR Action Fund, Entasis, QPex, Spero, VenatoRx, Pfizer, Merck, Gilead, bioMerieux and Accelerate Diagnostics. Jason A. Roberts reported grants from Qpex, Gilead, Pfizer, Sandoz, MSD, Summit Pharma and Cipla. Adam Irwin has received research grants and honoraria

- 415 from Gilead, and honoraria from bioMerieux unrelated to this work. All other authors declare
- 416 no conflicts of interest. Jason Roberts reported grants from Qpex, Gilead, Pfizer, Sandoz,
- 417 MSD, Summit Pharma and Cipla.

419		References
420 421	1.	Buehler SS, Madison B, Snyder SR, Derzon JH, Cornish NE, Saubolle MA, Weissfeld AS,
422		Weinstein MP, Liebow EB, Wolk DM. 2016. Effectiveness of Practices To Increase
423		Timeliness of Providing Targeted Therapy for Inpatients with Bloodstream Infections: a
424		Laboratory Medicine Best Practices Systematic Review and Meta-analysis. Clin Microbiol
425		Rev 29:59-103.
426	2.	Sinha M, Jupe J, Mack H, Coleman TP, Lawrence SM, Fraley SI. 2018. Emerging
427		Technologies for Molecular Diagnosis of Sepsis. Clin Microbiol Rev 31:e00089-17.
428	3.	Hindiyeh M, Smollan G, Grossman Z, Ram D, Robinov J, Belausov N, Ben-David D, Tal I,
429		Davidson Y, Shamiss A, Mendelson E, Keller N. 2011. Rapid detection of blaKPC
430		carbapenemase genes by internally controlled real-time PCR assay using bactec blood culture
431		bottles. J Clin Microbiol 49:2480-4.
432	4.	Taxt AM, Avershina E, Frye SA, Naseer U, Ahmad R. 2020. Rapid identification of
433		pathogens, antibiotic resistance genes and plasmids in blood cultures by nanopore sequencing.
434		Sci Rep 10:7622.
435	5.	Bauer MJ, Peri AM, Luftinger L, Beisken S, Bergh H, Forde BM, Buckley C, Cuddihy T, Tan
436		P, Paterson DL, Whiley DM, Harris PNA. 2022. Optimized Method for Bacterial Nucleic
437		Acid Extraction from Positive Blood Culture Broth for Whole-Genome Sequencing,
438		Resistance Phenotype Prediction, and Downstream Molecular Applications. J Clin Microbiol
439		60:e0101222.
440	6.	Irwin AD, Coin LJM, Harris PNA, Cotta MO, Bauer MJ, Buckley C, Balch R, Kruger P,
441		Meyer J, Shekar K, Brady K, Fourie C, Sharp N, Vlad L, Whiley D, Beatson SA, Forde BM,
442		Paterson D, Clark J, Hajkowicz K, Raman S, Bialasiewicz S, Lipman J, Schlapbach LJ,
443		Roberts JA. 2021. Optimising Treatment Outcomes for Children and Adults Through Rapid
444		Genome Sequencing of Sepsis Pathogens. A Study Protocol for a Prospective, Multi-Centre
445		Trial (DIRECT). Front Cell Infect Microbiol 11:667680.

- 446 7. Luftinger L, Majek P, Rattei T, Beisken S. 2023. Metagenomic Antimicrobial Susceptibility
- 447 Testing from Simulated Native Patient Samples. Antibiotics (Basel) 12:366.
- 448 8. De Coster W, D'Hert S, Schultz DT, Cruts M, Van Broeckhoven C. 2018. NanoPack:
- 449 visualizing and processing long-read sequencing data. Bioinformatics 34:2666-2669.
- 450 9. Li H. 2018. Minimap2: pairwise alignment for nucleotide sequences. Bioinformatics 34:3094451 3100.
- 452 10. Kolmogorov M, Yuan J, Lin Y, Pevzner PA. 2019. Assembly of long, error-prone reads using
 453 repeat graphs. Nat Biotechnol 37:540-546.
- 11. Nurk S, Meleshko D, Korobeynikov A, Pevzner PA. 2017. metaSPAdes: a new versatile
 metagenomic assembler. Genome Res 27:824-834.
- Li D, Luo R, Liu CM, Leung CM, Ting HF, Sadakane K, Yamashita H, Lam TW. 2016.
 MEGAHIT v1.0: A fast and scalable metagenome assembler driven by advanced
 methodologies and community practices. Methods 102:3-11.
- 459 13. Wu YW, Simmons BA, Singer SW. 2016. MaxBin 2.0: an automated binning algorithm to
 460 recover genomes from multiple metagenomic datasets. Bioinformatics 32:605-7.
- 461 14. Sieber CMK, Probst AJ, Sharrar A, Thomas BC, Hess M, Tringe SG, Banfield JF. 2018.
 462 Recovery of genomes from metagenomes via a dereplication, aggregation and scoring
 463 strategy. Nat Microbiol 3:836-843.
- 464 15. Wood DE, Lu J, Langmead B. 2019. Improved metagenomic analysis with Kraken 2.
 465 Genome Biol 20:257.
- 466 16. Manni M, Berkeley MR, Seppey M, Zdobnov EM. 2021. BUSCO: Assessing Genomic Data
 467 Quality and Beyond. Curr Protoc 1:e323.
- 468 17. Gurevich A, Saveliev V, Vyahhi N, Tesler G. 2013. QUAST: quality assessment tool for
 469 genome assemblies. Bioinformatics 29:1072-5.
- 470 18. Ferreira I, Beisken S, Lueftinger L, Weinmaier T, Klein M, Bacher J, Patel R, von Haeseler
- 471 A, Posch AE. 2020. Species Identification and Antibiotic Resistance Prediction by Analysis
- 472 of Whole-Genome Sequence Data by Use of ARESdb: an Analysis of Isolates from the
- 473 Unyvero Lower Respiratory Tract Infection Trial. J Clin Microbiol 58:e00273-20.

- 474 19. Bortolaia V, Kaas RS, Ruppe E, Roberts MC, Schwarz S, Cattoir V, Philippon A, Allesoe RL,
- 475 Rebelo AR, Florensa AF, Fagelhauer L, Chakraborty T, Neumann B, Werner G, Bender JK,
- 476 Stingl K, Nguyen M, Coppens J, Xavier BB, Malhotra-Kumar S, Westh H, Pinholt M, Anjum
- 477 MF, Duggett NA, Kempf I, Nykasenoja S, Olkkola S, Wieczorek K, Amaro A, Clemente L,
- 478 Mossong J, Losch S, Ragimbeau C, Lund O, Aarestrup FM. 2020. ResFinder 4.0 for
- 479 predictions of phenotypes from genotypes. J Antimicrob Chemother 75:3491-3500.
- 480 20. Feldgarden M, Brover V, Gonzalez-Escalona N, Frye JG, Haendiges J, Haft DH, Hoffmann
- 481 M, Pettengill JB, Prasad AB, Tillman GE, Tyson GH, Klimke W. 2021. AMRFinderPlus and
- the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial
 resistance, stress response, and virulence. Sci Rep 11:12728.
- 484 21. Clinical and Laboratory Standards Institute. 2015. Verification of Commercial Microbial
 485 Identification and Antimicrobial Susceptibility Testing Systems, 1st Edition, 1st ed. CLSI.
- 486 22. European Committee on Antimicrobial Susceptibility Testing. 2019. Breakpoint tables for
 487 interpretation of MICs and zone diameters version 9. EUCAST.
- 488 23. Matuschek E, Brown DF, Kahlmeter G. 2014. Development of the EUCAST disk diffusion
 489 antimicrobial susceptibility testing method and its implementation in routine microbiology
 490 laboratories. Clin Microbiol Infect 20:0255-66.
- 491 24. Wang W, Xi H, Huang M, Wang J, Fan M, Chen Y, Shao H, Li X. 2014. Performance of
 492 mass spectrometric identification of bacteria and yeasts routinely isolated in a clinical
 493 microbiology laboratory using MALDI-TOF MS. J Thorac Dis 6:524-33.
- 494 25. Godmer A, Benzerara Y, Normand AC, Veziris N, Gallah S, Eckert C, Morand P, Piarroux R,
 495 Aubry A. 2021. Revisiting Species Identification within the Enterobacter cloacae Complex by
 496 Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry. Microbiol
 497 Spectr 9:e0066121.
- 498 26. Gu W, Deng X, Lee M, Sucu YD, Arevalo S, Stryke D, Federman S, Gopez A, Reyes K, Zorn
- 499 K, Sample H, Yu G, Ishpuniani G, Briggs B, Chow ED, Berger A, Wilson MR, Wang C, Hsu
- 500 E, Miller S, DeRisi JL, Chiu CY. 2021. Rapid pathogen detection by metagenomic next-501 generation sequencing of infected body fluids. Nat Med 27:115-124.

- 502 27. Trung NT, Hien TT, Huyen TT, Quyen DT, Van Son T, Hoan PQ, Phuong NT, Lien TT, Binh
- 503 MT, Van Tong H, Meyer CG, Velavan TP, Song le H. 2016. Enrichment of bacterial DNA 504 for the diagnosis of blood stream infections. BMC Infect Dis 16:235.
- 505 28. Forde BM, De Oliveira DMP, Falconer C, Graves B, Harris PNA. 2022. Strengths and 506 caveats of identifying resistance genes from whole genome sequencing data. Expert Review 507 of Anti-infective Therapy 20:533-547.
- 508 29. Sereika M, Kirkegaard RH, Karst SM, Michaelsen TY, Sorensen EA, Wollenberg RD,

Albertsen M. 2022. Oxford Nanopore R10.4 long-read sequencing enables the generation of

- 510 near-finished bacterial genomes from pure cultures and metagenomes without short-read or 511 reference polishing. Nat Methods 19:823-826.
- 30. Humphries RM, Ambler J, Mitchell SL, Castanheira M, Dingle T, Hindler JA, Koeth L, Sei
 K, Development CM, Standardization Working Group of the Subcommittee on Antimicrobial
 Susceptibility T. 2018. CLSI Methods Development and Standardization Working Group
 Best Practices for Evaluation of Antimicrobial Susceptibility Tests. J Clin Microbiol
- 516 56:e01934-17.
- Martin S, Heavens D, Lan Y, Horsfield S, Clark MD, Leggett RM. 2022. Nanopore adaptive
 sampling: a tool for enrichment of low abundance species in metagenomic samples. Genome
 Biol 23:11.
- 520

509

522 TABLES

523 **Table 1:** Inclusion and exclusion criteria

Inclusion criteria	Exclusion criteria			
a) Age >1 month	a) inability to gain informed consent			
b) admitted to ICU	b) neonates (<1 month age)			
c) decision to treat for suspected sepsis [†]	c) imminent death likely			
d) blood cultures collected within 12h	d) palliative care intent			
e) commenced on IV antibiotics within 24h, or a	e) on renal replacement therapy *			
change in antibiotics initiated within 24h for a new episode of infection	f) use of extra-corporeal membrane oxygenation (ECMO) *			

* necessary as the main study included therapeutic drug monitoring and dose optimisation † defined as suspected / proven infection with evidence of end organ dysfunction

524

526 **Table 2: Species identification by conventional methods**

Species	Ν
Gram-positive (N=27)	
Staphylococcus aureus	10
Staphylococcus epidermidis	7
Streptococcus pneumoniae	2
Streptococcus pyogenes	1
Group C Streptococcus	1
Staphylococcus capitis	1
Staphylococcus lugdunensis	1
Staphylococcus haemolyticus	1
Enterococcus faecalis	1
Clostridium perfringens	1
Eggerthella lenta	1
Gram-negative (N=23)	1
Escherichia coli	7
Enterobacter cloacae complex	4
Klebsiella (Enterobacter) aerogenes	1
Pseudomonas aeruginosa	3
Klebsiella pneumoniae	3
Haemophilus influenzae	1
Stenotrophomonas maltophilia	1
Aeromonas sp.	1
Prevotella intermedia	1
Ochrobactrum anthropi	1
Polymicrobial (N=2)	
Escherichia coli + Enterobacter cloacae	1
Proteus mirabilis + Staphylococcus hominis	1
Total	52

527

528 **Table 3:** Performance of predictive MG-AST by species compared to Vitek 2, for samples

530

Species	Ν	Categorical Agreement (%)	Major Error (%)	Very Major Error (%)
Staphylococcus aureus	9	97.2	3.2	-
Escherichia coli	6	87.8	9.2	23.5
Klebsiella pneumoniae	3	93.8	6.5	0
Pseudomonas aeruginosa	3	52.4	47.6	-
Enterococcus faecalis	1	100	0	-
Klebsiella aerogenes	1	83.3	20	0
Streptococcus pneumoniae	1	66.7	33.3	-
Overall	24	89.3	10.5	12.1

531 Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference

532 method) 533

534 **Table 4:** Performance of predictive MG-AST by species compared to Vitek 2, for all samples

535 including those with both high confidence and exploratory-only predictions

⁵²⁹ with high quality predictions

5	3	6
J	J	U

Species	Ν	Categorical Agreement (%)	Major Error (%)	Very Major Error (%)
Staphylococcus aureus	9	96.6	2.9	7.7
Staphylococcus epidermidis	7	85.5	7.1	35
Escherichia coli	6	86.5	8.7	30
Enterobacter cloacae	3	92.3	7.4	8.3
Klebsiella pneumoniae	3	90	11.1	0
Pseudomonas aeruginosa	3	50	45.5	100
Aeromonas sp.	1	70	0	100
Enterococcus faecalis	1	100	0	0
Haemophilus influenzae	1	100	0	-
Klebsiella aerogenes	1	93.3	9.1	0
Ochrobactrum anthropi	1	87.5	0	33.3
Staphylococcus capitis	1	83.3	0	50
Staphylococcus haemolyticus	1	67.7	0	57.1
Staphylococcus lugdunensis	1	100	0	0
Streptococcus pneumoniae	1	75	25	-
Streptococcus pyogenes	1	100	0	0
Streptococcus dysgalactiae	1	100	0	-
Overall	42	87.7	8.3	28.4

537 Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference

538 method)

539

541 **Table 5:** Performance of MG-AST compared to Vitek MS, by species and compound, where

542 high quality predictions were available

Species	Compound	CA	ME	VME
	Compound	(%)	(%)	(%)
Enterococcus faecalis	Gentamicin	100	0	-
	Erythromcyin	100	-	0
	Linezolid	100	0	-
	Teicoplanin	100	0	-
	Vancomycin	100	0	-
Escherichia coli	Amikacin	83.3	16.7	-
	Amoxicillin + clavulanic acid	100	0	-
	Ampicillin	83.3	33.3	0
	Cefazolin	40	75	0
	Cefepime	100	0	0
	Cefoxitin	83.3	16.7	-
	Ceftazidime	100	0	0
	Ceftriaxone	100	0	0
	Ciprofloxacin	100	0	0
	Gentamicin	100	0	0
	Meropenem	100	0	-
	Sulfamethoxazole +trimethoprim	60	0	66.7
	Tobramycin	83.3	0	100
	Trimethoprim	83.3	0	25
Klebsiella (Enterobacter)	Amikacin	100	0	-
aerogenes	Amoxicillin + clavulanic acid	100	-	0
	Cefazolin	100	-	0
	Ceftazidime	0	100	-
	Ceftriaxone	0	100	-
	Ciprofloxacin	100	0	-
	Gentamicin	100	0	-
	Meropenem	100	0	-
	Sulfamethoxazole +trimethoprim	100	0	-
	Ticarcillin + clavulanic acid	100	0	-
	Tobramycin	100	0	-
	Trimethoprim	100	0	-
Klebsiella pneumoniae	Amikacin	100	0	-
	Amoxicillin + clavulanic acid	100	0	0
	Cefazolin	66.7	33.3	-
	Ceftazidime	100	0	-
	Ceftriaxone	100	0	-
	Ciprofloxacin	50	50	-
	Gentamicin	100	0	-
	Meropenem	100	0	-

	Sulfamethoxazole +trimethoprim	100	0	-
	Ticarcillin + clavulanic acid	100	0	-
	Tobramycin	100	0	-
	Trimethoprim	100	0	-
Pseudomonas aeruginosa	Amikacin	100	0	-
	Cefepime	33.3	66.7	-
	Ceftazidime	0	100	-
	Ciprofloxacin	33.3	66.7	-
	Gentamicin	66.7	33.3	-
	Meropenem	33.3	66.7	-
	Tobramycin	100	0	-
Staphylococcus aureus	Benzylpenicillin	100	0	0
	Ciprofloxacin	100	0	-
	Clindamycin	88.9	14.3	0
	Erythromycin	100	0	0
	Fusidic acid	100	0	-
	Gentamicin	100	0	-
	Linezolid	100	0	-
	Mupirocin	88.9	11.1	-
	Rifampicin	88.9	11.1	-
	Teicoplanin	100	0	-
	Tetracycline	100	0	-
	Vancomycin	100	0	-
Streptococcus pneumoniae	Benzylpenicillin	0	100	-
	Erythromycin	100	0	-
	Vancomycin	100	0	-
Overall	All agents	89.3	10.5	12.1

543 Note: blank cells reflect no data for calculations (e.g. no susceptibility / resistance seen in that species by reference method)

544

545

547 **Table 6:** Performance of MG-AST compared to Vitek MS for all compounds, where high

548 quality predictions were available

Compound	CA (%)	ME (%)	VME (%)
Amikacin	92.3	7.7	-
Amoxicillin + clavulanic acid	100	0	0
Ampicillin	83.3	33.3	0
Benzylpenicillin	90	50	0
Cefazolin	55.6	57.1	0
Cefepime	77.8	25	0
Cefoxitin	83.3	16.7	-
Ceftazidime	69.2	33.3	0
Ceftriaxone	88.9	12.5	0
Ciprofloxacin	85.7	15	0
Clindamycin	88.9	14.3	0
Erythromycin	100	0	0
Fusidic acid	100	0	-
Gentamicin	95.5	4.8	0
Linezolid	100	0	-
Meropenem	83.3	16.7	-
Sulfamethoxazole + trimethoprim	77.8	0	66.7
Ticarcillin + clavulanic acid	100	0	-
Tobramycin	92.3	0	100
Trimethoprim	90	0	25
Vancomycin	100	0	-
Overall	89.3	10.5	12.1

549 Note: blank cells reflect no data for calculations (e.g. no resistance seen in that species by reference

550 method) 551

553 FIGURE LEGENDS

Figure 1: Workflow for metagenomic and conventional analysis of positive blood cultures

555

- 556 Figure 2: Flow diagram for sample inclusion.
- 557 BC = blood culture; WGS-AST = whole genome sequencing antimicrobial susceptibility testing; QC =
- 558 quality control

- 560 Figure 3: Heat map comparing antimicrobial resistance genes detected from Nanopore-
- 561 generated sequences from blood culture broth extractions, compared to Illumina-generated
- sequences from pure cultured isolates from the same sample

Adults and children with sepsis in ICU





Excluded n=135

No positive blood culture

Excluded n=14 9 unavailable, 1 *Candida* sp.; 4 likely contaminants

Excluded n=10

2 polymicrobial, 3 no AST performed (anaerobes), 4 failed QC metrics, 1 AST agents not included in Ares database

